Wall Street Zen Upgrades Cue Biopharma (NASDAQ:CUE) to Strong-Buy

Key Points

• Wall Street Zen upgraded Cue Biopharma from “buy” to “strong-buy” in a report released Monday.
• Despite that upgrade, Weiss Ratings reaffirmed a “sell (e+) rating, and the consensus analyst view remains Sell.
• Cue Biopharma is a clinical-stage biotechnology company developing immunotherapies for cancer and infectious diseases, with its stock recently trading near $35 and a market cap of about $113.4 million.

Cue Biopharma (NASDAQ:CUE - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Monday.

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Cue Biopharma in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of "Sell".

Cue Biopharma Stock Performance

Shares of CUE stock opened at $35.00 on Monday. Cue Biopharma has a 12-month low of $4.97 and a 12-month high of $41.42. The stock has a market capitalization of $113.40 million, a P/E ratio of -3.64 and a beta of 2.37. The firm's 50 day moving average is $254.22 and its 200 day moving average is $360.69.

Hedge Funds Weigh In On Cue Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of CUE. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock worth $57,000 after buying an additional 73,000 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Cue Biopharma in the 3rd quarter worth $62,000. Boothbay Fund Management LLC purchased a new position in shares of Cue Biopharma during the 3rd quarter worth $439,000. GC Wealth Management RIA LLC boosted its stake in shares of Cue Biopharma by 35.0% during the 4th quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company's stock worth $1,415,000 after acquiring an additional 1,200,000 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc boosted its stake in shares of Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company's stock worth $135,000 after acquiring an additional 407,568 shares during the last quarter. 35.04% of the stock is currently owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.